LUCIANA OBA ONISHI KIKUCHI

(Fonte: Lattes)
Índice h a partir de 2011
13
Lattes
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/07 - Laboratório de Gastroenterologia Clínica e Experimental, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Revista / Livro: Clinics ×

Resultados de Busca

Agora exibindo 1 - 2 de 2
  • article 25 Citação(ões) na Scopus
    Clinical and pathological evaluation of fibrolamellar hepatocellular carcinoma: a single center study of 21 cases
    (2015) CHAGAS, Aline Lopes; KIKUCHI, Luciana; HERMAN, Paulo; ALENCAR, Regiane S. S. M.; TANI, Claudia M.; DINIZ, Marcio Augusto; PUGLIESE, Vincenzo; ROCHA, Manoel de Souza; D'ALBUQUERQUE, Luiz Augusto Carneiro; CARRILHO, Flair Jose; ALVES, Venancio A. F.
    OBJECTIVES: Fibrolamellar hepatocellular carcinoma is a rare primary malignant liver tumor that differs from conventional hepatocellular carcinoma in several aspects. The aim of this study was to describe the clinical, surgical and histopathological features of fibrolamellar hepatocellular carcinoma and to analyze the factors associated with survival. METHODS: We identified 21 patients with histopathologically diagnosed fibrolamellar hepatocellular carcinoma over a 22-year period. Clinical information was collected from medical records and biopsies, and surgical specimens were reviewed. RESULTS: The median age at diagnosis was 20 years. Most patients were female (67%) and did not have associated chronic liver disease. Most patients had a single nodule, and the median tumor size was 120 mm. Vascular invasion was present in 31% of patients, and extra-hepatic metastases were present in 53%. Fourteen patients underwent surgery as the first-line therapy, three received chemotherapy, and four received palliative care. Eighteen patients had ""pure fibrolamellar hepatocellular carcinoma,'' whereas three had a distinct area of conventional hepatocellular carcinoma and were classified as having ""mixed fibrolamellar hepatocellular carcinoma.'' The median overall survival was 36 months. The presence of ""mixed fibrolamellar hepatocellular carcinoma'' and macrovascular invasion were predictors of poor survival. Vascular invasion was associated with an increased risk of recurrence in patients who underwent surgery. CONCLUSION: Fibrolamellar hepatocellular carcinoma was more common in young female patients without chronic liver disease. Surgery was the first therapeutic option to achieve disease control, even in advanced cases. Vascular invasion was a risk factor for tumor recurrence. The presence of macrovascular invasion and areas of conventional hepatocellular carcinoma were directly related to poor survival.
  • article 21 Citação(ões) na Scopus
    Adherence to BCLC recommendations for the treatment of hepatocellular carcinoma: impact on survival according to stage
    (2017) KIKUCHI, Luciana; CHAGAS, Aline Lopes; ALENCAR, Regiane S. S. M.; TANI, Claudia; DINIZ, Marcio A.; D'ALBUQUERQUE, Luiz A. C.; CARRILHO, Flair Jose
    OBJECTIVES: This study sought to assess the adherence of newly diagnosed hepatocellular carcinoma patients to the Barcelona Clinic Liver Cancer system treatment guidelines and to examine the impact of adherence on the survival of patients in different stages of the disease. METHODS: This study included all patients referred for the treatment of hepatocellular carcinoma between 2010 and 2012. Patients (n=364) were classified according to the Barcelona Clinic Liver Cancer guidelines. Deviations from the recommended guidelines were discussed, and treatment was determined by a multidisciplinary team. The overall survival curves were estimated with the Kaplan-Meier method and were compared using the log-rank test. RESULTS: The overall rate of adherence to the guidelines was 52%. The rate of adherence of patients in each scoring group varied as follows: stage 0, 33%; stage A, 45%; stage B, 78%; stage C, 35%; and stage D, 67%. In stage 0/A, adherent patients had a significantly better overall survival than non-adherent patients (hazard ratio=0.19, 95% confidence interval (CI): 0.09-0.42; p<0.001). Among the stage D patients, the overall survival rate was worse in adherent patients than in non-adherent patients (hazard ratio=4.0, 95% CI: 1.67-9.88; p<0.001), whereas no differences were observed in patients in stages B or C. CONCLUSIONS: The rate of adherence to the Barcelona Clinic Liver Cancer staging system in clinical practice varies according to clinical disease stage. Adherence to the recommended guidelines positively impacts survival, especially in patients with early-stage disease.